Growth Metrics

Aurinia Pharmaceuticals (AUPH) Liabilities and Shareholders Equity (2019 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $527.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 3.97% year-over-year to $527.5 million, compared with a TTM value of $1.5 billion through Dec 2025, down 28.28%, and an annual FY2024 reading of $550.6 million, changed 0.47% over the prior year.
  • Liabilities and Shareholders Equity was $527.5 million for Q3 2025 at Aurinia Pharmaceuticals, up from $502.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $555.0 million in Q3 2023 and bottomed at $360.1 million in Q3 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $500.6 million, with a median of $516.6 million recorded in 2024.
  • Peak annual rise in Liabilities and Shareholders Equity hit 35.61% in 2022, while the deepest fall reached 13.34% in 2022.
  • Year by year, Liabilities and Shareholders Equity stood at $543.4 million in 2021, then fell by 13.34% to $470.9 million in 2022, then increased by 16.4% to $548.1 million in 2023, then grew by 0.47% to $550.6 million in 2024, then dropped by 4.2% to $527.5 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for AUPH at $527.5 million in Q3 2025, $502.6 million in Q2 2025, and $504.8 million in Q1 2025.